Skip to main content

Advertisement

Log in

Marked potentiation of the antitumour activity of chemotherapeutic drugs by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA)

  • Original Article
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Purpose. To determine whether there is a therapeutic interaction between the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and nine chemotherapy drugs against an early-passage mouse mammary tumour (MDAH-MCa-4), and to investigate the mechanism of any such interaction.

Methods and results. Female C3H/HeN mice bearing intramuscular MDAH-MCa-4 tumours were injected intraperitoneally with DMXAA (80 µmol/kg) or chemotherapy drug (at a range up to the maximum tolerated dose) alone, or coadministered. A small reduction in the dose of the chemotherapy drug was required in most cases, but the increase in antitumour effect was much greater than the increase in host toxicity (body weight loss). The therapeutic gain increased in the order 5-fluorouracil (no gain)<(etoposide, carboplatin, cyclophosphamide, doxorubicin, cisplatin)<(docetaxel, vincristine)<paclitaxel. The interaction with paclitaxel (31.6 µmol/kg) was striking, with coadministration of DMXAA extending the median tumour growth delay from 0.3 to 80 days with three of seven animals cured. The interaction showed a broad timing of the optimum with similar activity when paclitaxel was administered 4 h before to 1 h after DMXAA. No therapeutic synergy was obtained when paclitaxel was combined with the antivascular agent combretastatin A4 phosphate (227 µmol/kg), which induced only transient blood flow inhibition in this tumour, measured using the H33342 perfusion marker. Paclitaxel did not enhance the antivascular activity of DMXAA. Plasma and tumour concentrations of paclitaxel (and carboplatin), measured by LC-MS and ICP-MS respectively, were not elevated by combination with DMXAA.

Conclusions. There was a dramatic therapeutic interaction between DMXAA and standard chemotherapy drugs, particularly paclitaxel, against the MDAH-MCa-4 tumour, which was not due to a pharmacokinetic interaction or potentiation of antivascular activity. It is suggested that the major mechanism of synergy is killing of cells by DMXAA in poorly perfused regions of tumours that are inaccessible to chemotherapy drugs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Author information

Authors and Affiliations

Authors

Additional information

Electronic Publication

Rights and permissions

Reprints and permissions

About this article

Cite this article

Siim, B.G., Lee, A.E., Shalal-Zwain, S. et al. Marked potentiation of the antitumour activity of chemotherapeutic drugs by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA). Cancer Chemother Pharmacol 51, 43–52 (2003). https://doi.org/10.1007/s00280-002-0529-0

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-002-0529-0

Navigation